{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.2","upperLimit":"50.8","value":"43.4"}]}],"title":"Remission (CR/CRh*)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.6","upperLimit":"42.7","value":"35.4"}]}],"title":"Complete Remission"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"12.8","value":"7.9"}]}],"title":"Complete remission with only partial hematological"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"14.0","value":"9.0"}]}],"title":"Blast free hypoplastic or aplastic bone marrow"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"6.1","value":"2.6"}]}],"title":"Partial remission"}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"}],"units":"Participants"}],"description":"Complete Remission (CR):\n\n* bone marrow blasts ≤ 5%\n* no evidence of disease\n* full recovery of peripheral blood counts:\n\n  * platelets \\> 100,000/μL, and\n  * absolute neutrophil count (ANC) \\> 1,000/μL\n\nComplete Remission With Partial Hematological Recovery (CRh\\*):\n\n* bone marrow blasts ≤ 5%\n* no evidence of disease\n* partial recovery of peripheral blood counts:\n\n  * platelets \\> 50,000/μL, and\n  * ANC \\> 500/μL\n\nBlast Free Hypoplastic or Aplastic Bone Marrow:\n\n* bone marrow blasts ≤ 5%\n* no evidence of disease\n* insufficient recovery of peripheral counts: platelets ≤ 50,000/μL and/or ANC ≤ 500/μL\n\nPartial Remission:\n\n• bone marrow blasts 6% to 25% with at least a 50% reduction from Baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"Primary analysis set","reportingStatus":"POSTED","timeFrame":"From the first dose of blinatumomab until 30 days after the end of the last infusion during the core study, or until the data cut-off date of 10 October 2013; a maximum of 7.5 months.","title":"Best Response During the Core Study","type":"SECONDARY","unitOfMeasure":"percentage of participants"}